National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cabozantinib (COMETRIQ®) is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.

Rapid Review

Commenced Completed Outcome
10/07/2014 12/08/2014 Full pharmacoeconomic evaluation recommended at the submitted price

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.